Responses to targeted therapy among Organs Affected by Metastasis in Patients with Renal Cell Carcinoma are Organ-Specific
1 January 2020
Purpose: Previous reports showed that targeted therapy efficacy varied due to different metastatic organs in patients with metastatic renal cell carcinoma (mRCC). This study aimed to further evaluate the response and progression-free time (PFT) of individual metastatic organs.
Materials and Methods: Data from mRCC patients, who were treated with sunitinib between January 2008 to December 2018, were retrospectively reviewed. Individual metastatic organs were assessed separately by The Response Evaluation Criteria in Solid Tumors criteria.
Results: We evaluated response heterogeneity and PFT as characteristics of 281 individual organs affected by mRCC in 213 patients. The objective response rates in these organs were 72.7% in pancreas, 63.7% in spleen, 14.3% in adrenal glands, 13.5% in bone and soft tissue, 11.6% in lymph nodes, 11.6% in lungs, and 9.1% in liver. The median PFT was 15.2 months (95% confidence interval [CI] 2.7–27.7 months) for adrenal glands, 13.2 months (95% CI 3.5–22.9 months) for bone and soft tissue, 9.0 months (95% CI 7.6–10.4 months) for lymph nodes, 8.6 months (95% CI 6.3–10.9 months) for lungs, and 5.2 months (95% CI 2.9–7.5 months) for liver. Median PFT was not reached in pancreas and spleen, but was > 22.8 months and > 20.6 months, respectively.
Conclusion: Our results indicated that organs affected by metastasis may have individual responses to sunitinib treatment. The pancreas and spleen may have the best responses, and liver may have the worst response. Further research is needed to verify these findings.
- renal cell carcinoma
- targeted therapy
- objective response rate
How to Cite
Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. CA Cancer J Clin. 2019;69:7-34.
Capitanio U, Montorsi F. Renal cancer. Lancet. 2016;387:894-906.
Capitanio U, Bensalah K, Bex A, et al. Epidemiology of Renal Cell Carcinoma. Eur Urol. 2019;75:74-84.
Bianchi M, Sun M, Jeldres C, et al. Distribution of metastatic sites in renal cell carcinoma: a population-based analysis. Ann Oncol. 2012;23:973-980.
Albiges L, Choueiri T, Escudier B, et al. A systematic review of sequencing and combinations of systemic therapy in metastatic renal cancer. Eur Urol. 2015;67:100-110.
Choueiri TK, Motzer RJ. Systemic therapy for metastatic renal-cell carcinoma. N Engl J Med. 2017;376:354–366
Moran M, Nickens D, Adcock K, et al. Sunitinib for Metastatic Renal Cell Carcinoma: A Systematic Review and Meta-Analysis of Real-World and Clinical Trials Data. Target Oncol. 2019;14: 405-416.
Motzer RJ, Hutson TE, Tomczak P, et al. Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma. J Clin Oncol. 2009;27: 3584-3590.
Escudier B, Porta C, Schmidinger M, et al. Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2016;27(suppl 5):v58–v68.
Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45:228-247.
Klein CA. Parallel progression of primary tumours and metastases. Nat Rev Cancer. 2009;9:302-312.
Zeeshan R, Mutahir Z. Cancer metastasis - tricks of the trade. Bosn J Basic Med Sci. 2017;17:172-182.
Zhuang X, Zhang H, Hu G. Cancer and Microenvironment Plasticity: Double-Edged Swords in Metastasis. Trends Pharmacol Sci. 2019;40:419-29.
Miyake H, Matsushita Y, Watanabe H, et al. Clinical Outcomes of 42 Renal Cell Carcinoma Patients With Metastases Solely to the Lung Who Received Sorafenib as Second-line Systemic Therapy. Anticancer Res. 2019;39:1067-1072.
Golijanin B, Pereira J, Mueller-Leonhard C, et al. The natural history of renal cell carcinoma with isolated lymph node metastases following surgical resection from 2006 to 2013. Urol Oncol. 2019;37: 932-940.
Goto T, Inoue T, Kobayashi T, et al. Feasibility of laparoscopic adrenalectomy for metastatic adrenal tumors in selected patients: a retrospective multicenter study of Japanese populations. Int J Clin Oncol. 2020;25:126–134.
Drake FT, Beninato T, Xiong MX, et al. Laparoscopic adrenalectomy for metastatic disease: Retrospective cohort with long-term, comprehensive follow-up. Surgery. 2019;165:958–964.
Beuselinck B, Oudard S, Rixe O, et al. Negative impact of bone metastasis on outcome in clear-cell renal cell carcinoma treated with sunitinib. Ann Oncol. 2010;22:794–800.
Reichel LM, Pohar S, Heiner J, et al. Radiotherapy to bone has utility in multifocal metastatic renal carcinoma. Clin Orthop Relat Res. 2007;459:133–138.
Kim SH, Park WS, Park B, et al. A Retrospective Analysis of the Impact of Metastasectomy on Prognostic Survival According to Metastatic Organs in Patients With Metastatic Renal Cell Carcinoma. Front Oncol. 2019;9:413.
Kim SH, Kim JK, Park EY, et al. Liver metastasis and Heng risk are prognostic factors in patients with non-nephrectomized synchronous metastatic renal cell carcinoma treated with systemic therapy. PLoS One. 2019;14:e0211105.
Chatzizacharias NA, Rosich-Medina A, Dajani K, et al. Surgical management of hepato-pancreatic metastasis from renal cell carcinoma. World J Gastrointest Oncol. 2017;9:70-77.
Matsuda H, Tamada S, Kato M, et al. Transarterial chemoembolization of liver metastasis from renal cell carcinoma. Urol Case Rep. 2018;17:79-81.
Omari J, Heinze C, Damm R, et al. Radioablation of Hepatic Metastases from Renal Cell Carcinoma With Image-guided Interstitial Brachytherapy. Anticancer Res. 2019;39:2501-2508.
Sellner F. Observations on Solitary Versus Multiple Isolated Pancreatic Metastases of Renal Cell Carcinoma: Another Indication of a Seed and Soil Mechanism? Cancers (Basel). 2019;11:1379.
Abdul-Muhsin HM, Stern KL, Katariya NN, Castle EP. Robot assisted "en bloc" radical nephrectomy, splenectomy and distal pancreatectomy for renal cell carcinoma: case report and illustration of technique. J Robot Surg. 2016;10:375-378.
Kaur Grewal S, Doley RP, Roy K, et al. Isolated splenic metastasis from clear cell renal carcinoma - A case report. Int J Surg Case Rep. 2016;29:44-46.
Glinka J, Sanchez Claria R, Ardiles V, et al. The pancreas as a target of metastasis from renal cell carcinoma: Results of surgical treatment in a single institution. Ann Hepatobiliary Pancreat Surg. 2019;23:240-244.
Teranishi R, Hatanaka N, Hara S, et al. [Two Cases of Pancreatectomy for Pancreatic Metastasis from Renal Cell Carcinoma]. Gan To Kagaku Ryoho. 2019;46:561-563.
- Abstract Viewed: 0 times
- Just Accepted/6129 Downloaded: 0 times